EORTC Lymphoma Group

Open studyStudy to be openClosed study
20101
Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma (H11), a randomized phase III non-inferiority study of the EORTC Lymphoma Group and the Polish Lymphoma Research Group.
20051
The H10 EORTC/GELA/IIL randomized Intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiaphragmatic stage I/II Hodgkin's lymphoma.
20021
Gem-(R)CHOP versus (R)CHOP : a randomized Phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin's Lymphoma
20991
Diffuse large B cell and peripheral T cell non-Hodgkin's lymphomas in the elderly. Influence of prolonged oral etoposide added to CHOP combination chemotherapy in patients with good physiological status. An EORTC phase II-III trial including geriatric assessment and quality of life.
20013
Chlorambucil versus 2 X 2 Gy involved field radiotherapy in stage III/IV previously untreated follicular lymphoma patients.
20012
BEACOPP (4 cycles escalated + 4 cycles baseline) versus ABVD (8 cycles) in stage III & IV Hodgkin's Lymphoma
20992
Diffuse large B cell and peripheral T cell NHL in the frail elderly. Progressive and cautious treatment strategy in poor status patients. A phase II trial with emphasis on geriatric assessment and quality of life. Version 2.0 (13 December 2001)
20011
A randomized trial of BEAM + PBSCT versus single agent high-dose therapy followed by BEAM + PBSCT in patients with relapsed Hodgkin's disease (HD-R2 protocol).
20995
Treatment of mantle cell lymphomas at advanced stages: prospective randomized comparison of myeloabative radiochemotherapy followed by blood stem cell transplantation versus maintenance with interferon alpha in first remission after initial cytoreductive chemotherapy with an anthracycline containing combination. A European Intergroup Trial.
20971
A Phase III randomized study on low-dose total body irradiation and involved field radiotherapy in patients with localized, stages I and II, low grade non-Hodgkin's lymphoma
20981
Intergroup Collaborative Study (EORTC 20981) "Rituximab (Mabthera*) in remission induction and maintenance treatment of relapsed / resistant follicular non-Hodgkin's lymphoma : a phase III randomized clinical trial" lymphoma : a phase III randomised clinical trial - Intergroup Collaborative Study (EORTC 20981) Including Amenmdment 4 (28.6.2000)
20982
Prospective controlled trial in clinical stages I-II supradiaphragmatic Hodgkin'Disease. Evaluation of treatment efficacy, (long term) toxicity and Quality of Life in two different prognostic subgroups.
20961
A phase II clinical trial of anti-helicobacter pylori treatment in endoscopically diagnosed low-grade localized gastric lymphoma
20962
Evaluating the MBVP chemotherapy schedule followed by consolidating radiotherapy in non AIDS related primary CNS lymphoma (NAPCL)
20963
Marrow ablative chemo-radiotherapy and autologous stem cell transplantation followed by interferon - alpha maintenance treatment versus interferon-alpha maintenance alone after a chemotherapy induced remission in patients with stages III or IV follicular HNL. A prospective, randomised phase III clinical trial.
20932
Randomized investigation of the value of radiotherapy in complete remission after chemotherapy for patients with stage II, III or IV non Hodgkin's lymphoma of intermediate or high grade histology
20931
Protocol H8 for a prospective controlled trial in stage I-II supradiaphragmatic Hodgkin's disease. Evaluation of treatment efficacy and (long term) toxicity in three different prognostic subgroups. H8 Trial
20921
Fludarabine versus conventional combination chemotherapy (CVP) in patients with stages III and IV low grade malignant non-Hodgkin's lymphoma. A prospective randomized controlled phase III trial
20901
A prospective randomized controlled phase III trial on consolidation therapy with autologous bone marrow rescue after standard chemotherapy for intermediate grade and high grade non-Hodgkin's lymphoma
20884
Prospective randomized controlled trial of adjuvant involved field radiotherapy after MOPP/ABV hybrid chemotherapy in advanced Hodgkin disease. H34 Trial
20872
Phase III trial for the treatment of elderly patients (> 70 years) with stages II, III and IV non-Hodgkin's lymphomas of intermediate and high grade malignancy comparing CHOP vs a new combination of VP16, mitoxantrone and prednimustine
20882
Phase II Chemotherapy with Carbetimer in Patients with Stage III/IV Low-Grade non-Hodgkin's Lymphoma Who Have Relapsed After First-Line Treatment (Summary Last Modified 07/88)
20871A
Phase III for the treatment of localized intermediate and high grade gastrointestinal tract non-Hodgkin's lymphoma - stage I -
20871B
Phase III for the treatment of localized intermediate and high grade gastrointestinal tract non-Hodgkin's lymphoma - stage II -
20881
Phase III study on Hodgkin's disease supradiaphragmatic clinical stages I and II
20861
Phase II Chemotherapy with 5-AZA-2'-Deoxycytidine in Patients with Relapsed or Refractory Stage III/IV Hodgkin's Disease
20856
Maintenance of remission with recombinant alpha-2 Interferon (Roferon-A) in patients with stages III and IV low grade Non-Hodgkin's lymphoma
20855
Phase III trial comparing CHVmP/VCR-BLM vs modified ProMACE/MOPP regimen for patients with stages II, III, IV lymphomas of intermediate and high grade malignancy
20852
Phase II Salvage Chemotherapy with M-CAVe (CTX/ADR/VBL/MTX) Alternating with CEC (CCNU/VP-16/CLB) in MOPP-Refractory Hodgkin's Disease
20851
Phase II Chemotherapy Using ARA-C in Patients with Hodgkin's Disease Who Have Failed MOPP and ABVD Combination Chemotherapy
20811
Phase II trial in Hodgkin's disease, stage IIIB and IV, A and B with MOPP-ABVD (H3B4)
20751
Phase III trial comparing various induction schemes and various schedules of chemotherapy for maintenance in non-Hodgkin's lymphoma
20781
Controlled clinical trial on adjuvant therapy in the treatment of osteosarcomas of the limbs (03 Protocol)
20801
Phase III trial comparing total body irradiation and booster versus iceberg radiotherapy and CICS in stage III and IV non-Hodgkin's lymphoma with favorable histology (LR3)
20802
Phase III trial of induction therapy comparing CICS and iceberg radiotherapy versus CICS and bleomycin plus vindesine and iceberg radiotherapy followed by maintenance comparing CVP versus nothing in stage III and IV non-Hodgkin's lymphoma with unfavorable histology LR3)
20812
Phase III trial in non-Hodgkin's lymphomas stage II of favorable histologic types
20813
Phase III trial in non-Hodgkin's lymphomas stage II of unfavorable histologic types
20822
Phase III trial in the treatment of clinical stage I-II Hodgkin's disease for patients with unfavorable prognostic factors
20721
Phase III trial assessing the value of exploratory laparotomy or not in Hodgkin's disease patients with clinical stages I and II (H2 protocol)
20771
Phase III trial in stage I and II Hodgkin's disease (H5 protocol) comparing chemotherapy and radiotherapy to radiotherapy alone
20803BB
Pilot study in patients with Hodgkin's disease stage IIIB and IV: early prediction of response after two MOPP courses
20641
Phase III trial comparing radiotherapy and radiotherapy plus long-term chemotherapy (VBL q w for 2 years) in stage I and II Hodgkin's disease (H1)

Back to Group-list